Molecular, cellular and animal pharmacology of 5-AZA-2′-deoxycytidine-Reference-Cited by-同舟云学术

Molecular, cellular and animal pharmacology of 5-AZA-2′-deoxycytidine

Published:1985-01 Issue:3 Volume:30 Page:287-299
ISSN:0163-7258
Container-title:Pharmacology & Therapeutics
language:en
Short-container-title:Pharmacology & Therapeutics

Author:

Momparler Richard L.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference71 articles.

1. The effect of 5-azadeoxycytidine on cell growth and DNA methylation;Adams;Biochim. Biophys. Acta,1982

2. Incorporation of 5-aza-2′-deoxycytidine-5′-triphosphate into DNA: Interactions with mammalian DNA polymerase and DNA methylase;Bouchard;Molec. Pharmac.,1983

3. Antileukemic activity of 5-aza-2′-deoxycytidine and Cytarabine against intracerebral L1210 leukemia;Chabot;Cancer Treat. Rep.,1984

4. Effects of 5-aza-2′-deoxycytidine on survival and cell cycle progression of L1210 leukemic cells;Chabot;Leukemia Res.,1986

5. Kinetics of deamination of 5-aza-2′-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine and uracil arabinoside;Chabot;Biochem. Pharmac.,1983

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of decitabine combined with allogeneic hematopoietic stem cell transplantation in the treatment of recurrent and refractory acute myeloid leukemia (AML): A systematic review and meta-analysis;Medicine;2022-09-16

2. The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia;Advances in Therapy;2021-11-16

3. 5-Aza-4′-thio-2′-deoxycytidine, a New Orally Bioavailable Nontoxic “Best-in-Class”: DNA Methyltransferase 1–Depleting Agent in Clinical Development;Journal of Pharmacology and Experimental Therapeutics;2021-09-09

4. DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application;Clinical Epigenetics;2021-08-27

5. Low-dose decitabine as part of a modified Bu-Cy conditioning regimen improves survival in AML patients with active disease undergoing allogeneic hematopoietic stem cell transplantation;Bone Marrow Transplantation;2021-02-26